Revenue Financing for the Life Sciences
Leveraging deep scientific and commercial expertise to deliver structured,
non-dilutive financing to the high-growth life sciences sector

  ✓   Timely access to non-dilutive growth capital that isn't debt
        Royalty interest financing provides access to capital in exchange for future revenue         without the risks associated with debt and serves as a complement to equity financing         activities
‍
  ✓   No impact to control or ownership of intellectual property
        Royalty obligations created and managed by SVRN leaves intellectual property in the         hands of the existing owner(s) who maintain control over the requisite R&D and         commercialization activities
‍
  ✓   Royalty terms and duration designed around capital needs
        Scope, duration, and terms of the royalty obligation are established based on capital         needs, allowing for narrow collateral on specific products or IP assets

  ✓   Access exclusive royalty assets uncorrelated with macro volatility
        Scientific royalties are high-quality assets that generate predictable cash flows in sectors         with inelastic demand such as medtech and biopharma, but have traditionally been         accessible only for large institutional investors
‍
  ✓   Fractional investment opportunities enable portfolio diversification
        SVRN enables fractional ownership in scientific royalties allowing for flexible investment         sizes for accredited investors and the opportunity to build a portfolio of cash-flowing         assets that perform well in inflationary environments
‍
  ✓   Receive distributions from productive intellectual property
        SVRN allows investors to get direct exposure to revenue distributions from specific         intellectual property in a manner that is distinct from traditional equity investment